Restoring Mitochondrial Homeostasis to Prevent Cisplatin Nephrotoxicity: Targeting Ferroptosis With the Novel Compound 84-B10

Restoring Mitochondrial Homeostasis to Prevent Cisplatin Nephrotoxicity: remains a cornerstone chemotherapeutic agent for the treatment of multiple solid tumors, yet its clinical utility is substantially limited by dose-dependent nephrotoxicity. Accumulating evidence indicates that cisplatin-induced acute kidney injury (AKI) is driven not only by conventional apoptotic pathways but also by ferroptosis and mitochondrial dysfunction. Recent advances have highlighted mitochondrial reactive oxygen species (mtROS) as a critical upstream trigger linking oxidative stress to ferroptotic cell death in renal tubular epithelial cells. In this context, the novel 3-phenylglutaric acid derivative 84-B10 has emerged as a promising nephroprotective candidate.

Preclinical studies demonstrate that 84-B10 effectively alleviates cisplatin-induced renal injury without compromising antitumor efficacy. Mechanistically, 84-B10 suppresses lipid peroxidation, restores key ferroptosis defense systems, and preserves mitochondrial structure and function. Notably, the compound reduces mtROS accumulation and enhances mitochondrial antioxidant capacity, thereby interrupting the pathogenic cascade that leads to ferroptosis. Comparative analyses reveal that, unlike classical ferroptosis inhibitors, 84-B10 provides upstream mitochondrial protection, resulting in more comprehensive preservation of renal homeostasis.

These findings position mitochondrial oxidative stress as a central therapeutic target in cisplatin-induced AKI and underscore the potential of 84-B10 as an adjunct strategy to improve chemotherapy tolerability. Targeting mtROS-mediated ferroptosis may represent a broader paradigm for the development of mechanism-based interventions against drug-induced nephrotoxicity and other oxidative stress-related renal disorders.

Cisplatin-Induced Nephrotoxicity: An Unmet Clinical Challenge

Cisplatin is one of the most effective and widely prescribed platinum-based chemotherapeutic agents, playing a central role in the treatment of a broad range of solid tumors, including lung, ovarian, bladder, head and neck, and testicular cancers. Its potent antitumor activity is primarily attributed to its ability to induce DNA crosslinking, thereby triggering apoptosis in rapidly dividing cancer cells. Despite its proven clinical efficacy, the therapeutic use of cisplatin is significantly constrained by severe dose-limiting toxicities, among which nephrotoxicity remains the most prominent and clinically challenging adverse effect.

Cisplatin-induced acute kidney injury (AKI) occurs in approximately 20–30% of patients, even with adequate hydration and supportive care. Renal tubular epithelial cells, particularly those in the proximal tubules, preferentially accumulate cisplatin, rendering the kidney highly susceptible to injury. Clinically, cisplatin nephrotoxicity manifests as elevated serum creatinine, reduced glomerular filtration rate, electrolyte disturbances, and, in severe cases, irreversible renal failure. These complications often necessitate dose reduction, treatment delay, or discontinuation, ultimately compromising anticancer efficacy and patient outcomes.

Current preventive strategies for cisplatin-induced nephrotoxicity are largely limited to non-specific measures such as aggressive hydration, diuretics, and magnesium supplementation. While these approaches provide partial protection, they fail to address the underlying molecular mechanisms driving renal injury. Importantly, no FDA-approved targeted therapies are currently available to effectively prevent or treat cisplatin-induced AKI without interfering with its antitumor activity. This represents a significant unmet clinical need in oncology and nephrology.

In recent years, advances in cell death biology have reshaped our understanding of cisplatin nephrotoxicity. Beyond classical apoptosis and necrosis, emerging evidence highlights the involvement of regulated cell death pathways, including ferroptosis, a form of iron-dependent cell death characterized by uncontrolled lipid peroxidation. In parallel, mitochondrial dysfunction and excessive mitochondrial reactive oxygen species (mtROS) production have been increasingly recognized as central contributors to cisplatin-induced renal damage. These insights suggest that oxidative stress, mitochondrial injury, and ferroptosis are not isolated events but interconnected processes that collectively drive tubular cell death and kidney dysfunction.

Understanding these mechanisms has opened new avenues for therapeutic intervention. Targeting mitochondrial oxidative stress and ferroptosis represents a promising strategy to mitigate cisplatin-induced nephrotoxicity while preserving its anticancer efficacy. Against this backdrop, the development of novel nephroprotective agents with defined molecular targets is of considerable scientific and clinical interest.

Ferroptosis and Mitochondrial Dysfunction in Cisplatin-Induced Acute Kidney Injury

Cisplatin-induced acute kidney injury (AKI) is increasingly recognized as a complex pathological process involving multiple, tightly interconnected mechanisms of regulated cell death. While apoptosis and necrosis were historically considered the dominant drivers of renal tubular injury, recent advances have identified ferroptosis as a critical contributor to cisplatin-induced nephrotoxicity. Ferroptosis is a distinct, iron-dependent form of cell death characterized by excessive lipid peroxidation and loss of plasma membrane integrity, setting it apart from classical apoptotic pathways.

In the kidney, proximal tubular epithelial cells are particularly vulnerable to ferroptosis due to their high metabolic activity, abundant mitochondria, and sensitivity to oxidative stress. Cisplatin disrupts intracellular redox balance by promoting iron accumulation, impairing antioxidant defenses, and triggering the peroxidation of polyunsaturated fatty acids within cellular membranes. Central to ferroptosis regulation are key protective systems such as glutathione peroxidase 4 (GPX4) and the cystine/glutamate antiporter system Xc⁻ (SLC7A11). Cisplatin exposure has been shown to downregulate these ferroptosis suppressors, leading to unchecked lipid peroxide accumulation and subsequent tubular cell death.

Mitochondrial dysfunction plays a pivotal role in amplifying ferroptotic signaling during cisplatin-induced AKI. Mitochondria are both a major source and a primary target of reactive oxygen species (ROS). Under cisplatin challenge, mitochondrial DNA damage, impaired electron transport chain activity, and loss of mitochondrial membrane potential result in excessive mitochondrial ROS (mtROS) generation. This burst of mtROS not only exacerbates oxidative stress but also accelerates lipid peroxidation, thereby fueling ferroptosis in renal tubular cells.

Importantly, emerging evidence suggests that mtROS act upstream of ferroptosis in cisplatin-induced kidney injury. Elevated mtROS can overwhelm endogenous antioxidant systems, including mitochondrial superoxide dismutases (SODs), further destabilizing mitochondrial homeostasis. The resulting oxidative environment creates favorable conditions for iron-catalyzed lipid peroxidation, effectively linking mitochondrial injury to ferroptotic cell death. This mechanistic hierarchy is supported by studies showing that mitochondrial-targeted antioxidants and SOD mimetics can attenuate both ferroptosis markers and renal dysfunction in experimental models of cisplatin nephrotoxicity.

Together, these findings highlight a pathogenic axis in which cisplatin-induced mitochondrial damage leads to excessive mtROS production, suppression of ferroptosis defense pathways, and ultimately tubular cell death. Understanding the interplay between mitochondrial dysfunction and ferroptosis not only provides mechanistic insight into cisplatin-induced AKI but also identifies new therapeutic targets. Interventions aimed at restoring mitochondrial redox balance and preventing ferroptosis may offer a more effective and targeted approach to protecting renal function during cisplatin chemotherapy.

Discovery of 84-B10: A Novel 3-Phenylglutaric Acid Derivative With Nephroprotective Potential

The growing recognition of ferroptosis and mitochondrial oxidative stress as central drivers of cisplatin-induced acute kidney injury (AKI) has intensified efforts to identify small molecules capable of targeting these pathways without compromising anticancer efficacy. Within this context, the discovery of 84-B10 represents a significant advance in the development of mechanism-based nephroprotective agents. 84-B10 is a novel 3-phenylglutaric acid derivative chemically defined as 5-[[2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-5-oxo-3-phenylpentanoic acid, designed to modulate oxidative stress–related cellular injury.

3-Phenylglutaric acid derivatives have attracted attention in medicinal chemistry due to their structural versatility and capacity to interact with redox- and metabolism-related targets. The rational exploration of this scaffold enabled the identification of 84-B10 as a compound with favorable bioactivity in renal injury models. Importantly, early evaluations demonstrated that 84-B10 does not promote tumor growth or interfere with cisplatin’s anticancer effects, a critical requirement for any adjunct therapy used in oncology settings.

The protective role of 84-B10 in cisplatin-induced AKI was first supported by genome-wide transcriptome analyses. These studies revealed that 84-B10 treatment counteracted cisplatin-induced transcriptional changes associated with ferroptosis, including pathways related to lipid peroxidation, iron metabolism, and oxidative stress responses. Notably, genes involved in ferroptosis suppression and mitochondrial homeostasis were restored toward baseline levels following 84-B10 administration, suggesting a targeted regulatory effect rather than nonspecific cytoprotection.

Functional validation in both in vivo and in vitro models further substantiated these transcriptomic findings. 84-B10 markedly reduced lipid peroxide accumulation and reversed the downregulation of key ferroptosis defense systems under cisplatin challenge. These effects were accompanied by improved renal histopathology and preserved tubular epithelial integrity. The compound’s dual action on mitochondrial oxidative stress and ferroptotic signaling distinguishes it from classical antioxidants or single-pathway inhibitors.

Collectively, the discovery of 84-B10 highlights the therapeutic potential of small molecules that integrate mitochondrial protection with ferroptosis inhibition. By leveraging transcriptomic insights and rational chemical design, 84-B10 emerges as a promising lead compound for preventing cisplatin-induced nephrotoxicity. Its identification also underscores the value of targeting upstream oxidative stress mechanisms to modulate regulated cell death pathways in kidney disease.

Mechanistic Insights: How 84-B10 Protects the Kidney From Cisplatin-Induced Injury

Understanding the mechanistic basis of nephroprotection is essential for evaluating the therapeutic potential of novel compounds in cisplatin-induced acute kidney injury (AKI). Experimental evidence demonstrates that the 3-phenylglutaric acid derivative 84-B10 exerts robust protective effects by targeting both mitochondrial oxidative stress and ferroptotic cell death pathways. This dual mechanism differentiates 84-B10 from conventional antioxidants and single-pathway ferroptosis inhibitors.

One of the hallmark features of cisplatin-induced AKI is excessive lipid peroxidation within renal tubular epithelial cells, a defining event in ferroptosis. Treatment with 84-B10 significantly reduced lipid peroxide accumulation in both in vivo and in vitro cisplatin injury models. Concomitantly, the expression and activity of key ferroptosis suppressors were restored, indicating that 84-B10 actively reestablishes endogenous defense systems rather than merely scavenging reactive species. These findings align with transcriptomic data showing reversal of ferroptosis-associated gene dysregulation following 84-B10 administration.

Mitochondrial integrity emerged as a central target of 84-B10 activity. Cisplatin exposure typically leads to mitochondrial structural damage, impaired membrane potential, and dysfunction of the electron transport chain, all of which contribute to excessive mitochondrial reactive oxygen species (mtROS) production. 84-B10 markedly inhibited mtROS accumulation and preserved mitochondrial morphology and function. Importantly, the compound restored the activity of mitochondrial superoxide dismutases (SODs), key enzymes responsible for detoxifying superoxide radicals and maintaining redox homeostasis within mitochondria.

Comparative pharmacological analyses further clarified the unique mechanism of 84-B10. The compound exhibited effects comparable to MnTBAP, a well-characterized cell-permeable SOD mimetic, in eliminating mtROS and restoring mitochondrial homeostasis under cisplatin challenge. This similarity underscores the role of mitochondrial oxidative stress suppression as a primary mode of action for 84-B10. In contrast, when compared to liproxstatin-1, a canonical ferroptosis inhibitor, important mechanistic differences became evident. While both compounds effectively attenuated ferroptosis markers and reduced lipid peroxidation, liproxstatin-1 failed to prevent mitochondrial dysfunction or mtROS accumulation.

Fig. 1 Mechanism of 84-B10–Mediated Protection Against Cisplatin-Induced Kidney Injury Mechanism-Focused

These observations suggest that mitochondrial oxidative stress acts upstream of ferroptosis in cisplatin-induced tubular injury. By targeting mtROS generation and reinforcing mitochondrial antioxidant defenses, 84-B10 interrupts the pathogenic cascade at an earlier stage than ferroptosis-specific inhibitors. This upstream intervention not only suppresses ferroptotic cell death but also preserves overall mitochondrial homeostasis, offering a more comprehensive protective strategy.

Collectively, these mechanistic insights position 84-B10 as a promising therapeutic candidate that bridges mitochondrial protection and ferroptosis inhibition. Its ability to restore redox balance and mitochondrial function provides a strong rationale for further development as a targeted nephroprotective agent in cisplatin-based chemotherapy.

Therapeutic Implications and Future Perspectives

The identification of 84-B10 as a potent modulator of mitochondrial oxidative stress and ferroptosis has important therapeutic implications for the prevention and treatment of cisplatin-induced acute kidney injury (AKI). Current clinical management of cisplatin nephrotoxicity relies largely on supportive measures rather than mechanism-based interventions. The ability of 84-B10 to directly target upstream pathogenic events offers a promising shift toward more precise and effective nephroprotective strategies in oncology.